Hans Fredrik Mattsson

Director/Board Member chez DEVYSER DIAGNOSTICS AB

Profil

Hans Fredrik Mattsson is currently the Chairman at Celemi International AB, the Director at Dipylon Medical AB, the Director at Investment AB Bure, the Director at Bure Growth AB, and the Independent Director at Devyser Diagnostics AB.
Previously, he served as the Chief Executive Officer at Vittra Utbildning AB and Anew Learning AB.
He was also the Chairman at Xvivo Perfusion AB from 2012 to 2018, and the Chairman at BioLamina AB.
Additionally, he worked as the Investment Director at Bure Equity AB from 2009 to 2018, and as the Independent Director at Vitrolife AB from 2007 to 2018.
He held positions such as Director at Mercuri International Group AB and MedCap AB, and Investment Director at Bure Equity (Private Equity) from 2010 to 2018.
He also served as a Director at Energo-Retea AB, Celemiab Group AB, Theducation AB, Life Genomics AB, and Skanditek Industriförvaltning AB.
Prior to that, he was the Vice President-Homecare at Gambro Renal Products, Inc. and a Management Consultant at McKinsey & Co. Service AB.

Postes actifs de Hans Fredrik Mattsson

Sociétés	Poste	Début
DEVYSER DIAGNOSTICS AB	Director/Board Member	01/01/2022
Celemi International AB	Chairman	-
Bure Growth AB	Director/Board Member	-
Investment AB Bure	Director/Board Member	-
Dipylon Medical AB	Director/Board Member	-

Anciens postes connus de Hans Fredrik Mattsson

Sociétés	Poste	Fin
Bure Equity (Private Equity)	Private Equity Investor	31/10/2018
BURE EQUITY AB	Chief Investment Officer	15/09/2018
XVIVO PERFUSION AB	Chairman	27/04/2018
Energo-Retea AB	Director/Board Member	26/12/2012
░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░